GE HealthCare to announce third quarter 2026 results on October 28, 2026

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will announce its third quarter 2026 financial results before the market opens on Wednesday, October 28, 2026. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also wil.

Business Wire • Oct 7, 2026

GE HealthCare Expands U.S. PET Radiopharma Reach With SOFIE Deal

GEHC's $945M SOFIE Biosciences deal will expand its U.S. PET radiopharmaceutical footprint and boost exposure to precision care growth.

Zacks Investment Research • Oct 6, 2026

GE HealthCare is expected to announce Monday a $945 million cash purchase of a manufacturer of radioactive substances used in medical imaging procedures like PET scans

The deal expands GE HealthCare's footprint in radiopharmaceuticals, its fastest-growing segment.

WSJ • Oct 5, 2026

GE HealthCare to buy Sofie Biosciences for $945 million to strengthen radiopharma business

Medical device maker GE HealthCare said on Monday it would buy privately held Sofie Biosciences for $945 million in ​cash, in a move that strengthens its ability ‌to manufacture and distribute PET imaging drugs.

Reuters • Oct 5, 2026

GE HealthCare Bets $945M on Fast-Growing Market With Sofie Biosciences Acquisition

GE Healthcare Technologies will purchase radiopharmaceutical company Sofie Biosciences to expand into a lucrative therapeutic area.

Barrons • Oct 5, 2026

GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced a definitive agreement to acquire SOFIE Biosciences, a leading U.S.-based CMO for PET radiopharmaceuticals, from Trilantic North America, for a purchase price of $945 million paid in cash. The transaction is expected to close in the first half of 2027, subject to closing conditions, including regulatory approvals, at which time SOFIE Biosciences will become part of GE HealthCare's PDx segment. The acquisition of SOFIE Biosci.

Business Wire • Oct 5, 2026

GE HealthCare Technologies Inc. (GEHC) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G.

GlobeNewsWire • Oct 5, 2026

Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

LOS ANGELES, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ: GEHC) investors concerning the Company's possible violations of the federal securities laws.

GlobeNewsWire • Oct 5, 2026

Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

LOS ANGELES, Oct. 02, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ: GEHC) on behalf of investors concerning the Company's possible violations of federal securities laws.

GlobeNewsWire • Oct 2, 2026

GEHC vs. SYK: Which Stock Should Value Investors Buy Now?

Investors with an interest in Medical - Products stocks have likely encountered both GE HealthCare Technologies (GEHC) and Stryker (SYK). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • Oct 2, 2026